Quick Answer
Livagen is the synthetic tetrapeptide Lys-Glu-Asp-Ala (KEDA), designed by Khavinson's group from the amino acid composition of a calf liver peptide extract. Its most documented effect is chromatin decondensation in cultured lymphocytes from elderly donors, not in liver cells. Direct liver findings are limited to rat hepatocyte and explant cultures, and the hepatitis and tumour data appear only in patents. Almost all of the work comes from one research network, much of it in Russian-language and regional journals, without independent replication.
Livagen is one of the better documented Khavinson bioregulators, with around twenty PubMed records. That is still a small literature, and it is less about the liver than the name suggests: most of the published papers are chromosome studies in human white blood cells.
Sequence and identity
Livagen is lysyl-glutamyl-aspartyl-alanine, written Lys-Glu-Asp-Ala or KEDA (H-Lys-Glu-Asp-Ala-OH). Several papers from the group pair the name with this sequence explicitly [1, 2, 3], and the group's European patent gives a molecular formula of C18H31N5O9 and a molecular weight of about 461.5 g/mol [4]. Livagen shares its first three residues with Testagen (KEDG), Prostamax (KEDP) and Pancragen (KEDW); in this family the final residue is what is supposed to separate a liver peptide from a testicular, prostate or pancreatic one.
Origin and tissue association
Unlike some bioregulators, Livagen's liver assignment has a documented origin. A 2001 paper describes it as obtained by directed chemical synthesis based on amino acid analysis of liver polypeptide preparations [1], and the group's 2020 review names the source as Ventvil, a polypeptide complex extracted from calf liver [3]. That is the standard bioregulator path from organ extract (cytomedine) to short synthetic peptide (cytogen). The liver label is inherited from the extract; whether the synthetic peptide acts specifically on liver is a separate question.
Proposed mechanism
Two mechanisms appear in the literature. The main one is the class hypothesis that short peptides reach the nucleus and loosen chromatin. A genetics group at Tbilisi State University, working with Khavinson, reported that Livagen added to cultured lymphocytes from people aged 75 to 88 activated ribosomal genes, decondensed pericentromeric heterochromatin on chromosomes 1 and 9, and loosened facultative heterochromatin. The authors interpret this as releasing genes silenced by age-related chromatin condensation [5, 6]. The second mechanism is unrelated to DNA: in human serum in vitro, Livagen inhibited enkephalin-degrading enzymes at micromolar concentrations, more potently than Epitalon, without binding mu or delta opioid receptors [2].
We found no peer-reviewed study of either mechanism in liver tissue: the chromatin work used white blood cells and the enzyme work used serum.
What the studies actually show
| Model | What was reported | Source |
|---|---|---|
| Rat hepatocyte culture | Higher protein synthesis, largest in cells from old rats | Peer-reviewed, Russian [1] |
| Rat liver explants (organ culture) | Explant growth, presented as tissue specificity | Peer-reviewed [7] |
| Lymphocytes from elderly donors (in vitro) | Chromatin decondensation; ribosomal gene activation | Peer-reviewed [5, 6, 8] |
| Human serum (in vitro) | Inhibition of enkephalin-degrading enzymes | Peer-reviewed, Russian [2] |
| Young and old rats | Digestive enzyme activity in old rats shifted towards young levels | Peer-reviewed, Russian [9] |
| Rats with toxic hepatitis or a transplanted liver tumour | Less liver damage; slower tumour growth | Patent only [4] |
| Patients with chronic hepatitis | 23 treated compared with 12 conventionally treated | Patent only, no described randomisation or blinding [4] |
The liver cell work is small. Brodskii and colleagues measured the rhythm of protein synthesis in cultured hepatocytes from rats aged 1 to 24 months and found that Livagen raised protein synthesis, most in cells from old animals, while Epitalon had no effect in the same system [1]. Khavinson's 2001 organ culture report stated that Livagen stimulated the growth of rat liver explants, as Cortagen did for cortex and Vilon for thymus, and presented this as evidence of tissue specificity [7].
The disease-model evidence is thinner than it looks. The group's 2020 review describes protective effects in rats with acute toxic hepatitis, but the sources it cites for those results are two patents rather than journal articles [3]. The European patent describes rats with carbon tetrachloride induced hepatitis, rats with a transplanted hepatoma, and 23 patients with chronic persistent hepatitis compared with 12 conventionally treated patients, with no randomisation or blinding described [4]. Patent examples are not peer reviewed, and we found no full journal publication of these experiments.
The lymphocyte series is the largest body of Livagen work. Beyond cells from elderly donors, the Tbilisi group tested Livagen on lymphocytes exposed to cobalt ions and on cells from patients with atherosclerosis or breast cancer, reporting fewer chromosomal abnormalities or other signs of genomic damage [8, 10, 11]. These are cell culture findings in blood cells, published largely in Georgian Medical News.
How strong is the evidence?
Livagen has more published work than most bioregulators, and it is still early-stage evidence. Every study we found involves Khavinson as an author or his long-standing collaborators in Tbilisi, Moscow and Chita. Much of it is in Russian or in regional journals, and the animal disease data sit in patents. We found no report of a Livagen effect reproduced by an unaffiliated group, and no registered clinical trial. The chromatin findings are the most consistent thread, but they come from one network's methods applied to blood cells, which is a long way from a liver-specific effect.
For a researcher, the open questions are straightforward: whether KEDA changes chromatin or gene expression in hepatocytes, whether any effect is specific to liver compared with other tissues and control peptides, and whether any result survives independent replication.
Where Livagen fits
Livagen is one of the compounds covered in our overview of bioregulator peptides and the Khavinson research, which explains the cytomedine and cytogen history, the DNA interaction hypothesis and the evidence problems shared across the class. The testicular member of the same Lys-Glu-Asp series is covered in Testagen: what the research shows.
References
- Brodskii VIa, et al. (2001). Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen. Izvestiia Akademii Nauk. Seriia Biologicheskaia (in Russian). PubMed 15926314
- Kost NV, et al. (2003). Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. Izvestiia Akademii Nauk. Seriia Biologicheskaia (in Russian). PubMed 12942748
- Kuznik BI, et al. (2020). The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Advances in Gerontology (Uspekhi Gerontologii), 33(1) (in Russian). PubMed 32362099
- Khavinson VKh. (2004). Tetrapeptide stimulating functional activity of hepatocytes and its therapeutical use. European patent EP1325026, granted 18 August 2004. Patent, not peer reviewed; no PubMed record.
- Khavinson VKh, et al. (2002). Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bulletin of Experimental Biology and Medicine, 134(4). PubMed 12533768
- Khavinson VKh, Lezhava TA, Malinin VV. (2004). Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine, 137(1). PubMed 15085253
- Khavinson VK. (2001). Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine, 132(2). PubMed 11713572
- Lezhava T, Jokhadze T. (2007). Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Annals of the New York Academy of Sciences, 1100. PubMed 17460203
- Timofeeva NM, et al. (2005). Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages. Advances in Gerontology (Uspekhi Gerontologii), 16 (in Russian). PubMed 16075683
- Dzhokhadze TA, et al. (2014). Genomic instability in atherosclerosis. Georgian Medical News (in Russian). PubMed 25541832
- Jokhadze T, et al. (2017). Evaluation of genomic parameters in ductal breast cancer patients and the ability of it's correction. Georgian Medical News (in Russian). PubMed 28574395